 |
|
C-Reactive Protein and Cardiovascular Risk in the Framingham Study—Reply
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
In reply
We thank Ridker and colleagues for their interest in our recent publication.1 C-reactive protein level clearly predicts risk for cardiovascular disease events, but the extent to which CRP level improves such estimates is controversial.
A critical issue is the identification of individuals with higher levels of CRP with the assay we used compared with the assay mentioned by Ridker et al. In 2002, we performed a crossover analysis to compare the Hemagen assay (Hemagen Diagnostics Inc, Columbia, Md) we used and the Dade Behring nephelometric assay (Dade Behring Inc, Deerfield, Ill). We found a very high correlation of 0.98 and high degree of agreement for CRP level categorized by quartiles. Similar results have been obtained by others in comparisons of medium and high-sensitivity CRP assays.2 We share Ridker and colleagues' interest in the development of a CRP standardization program, but at present there is no formal program in . . . [Full Text of this Article]
AUTHOR INFORMATION
Peter W. F. Wilson, MD;
Michael Pencina, PhD;
Ralph B. D’Agostino, Sr, PhD;
Christopher J. O’Donnell, MD, MPH
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED ARTICLES
C-Reactive Protein and Cardiovascular Risk in the Framingham Study
Paul Ridker, Nader Rifai, Wolfgang Koenig, and Roger S. Blumenthal
Arch Intern Med. 2006;166(12):1327-1328.
EXTRACT
| FULL TEXT
C-Reactive Protein and Risk of Cardiovascular Disease in Men and Women From the Framingham Heart Study
Peter W. F. Wilson, Byung-Ho Nam, Michael Pencina, Ralph B. D’Agostino, Sr, Emelia J. Benjamin, and Christopher J. O’Donnell
Arch Intern Med. 2005;165(21):2473-2478.
ABSTRACT
| FULL TEXT
|
